Related Experiment Video
Updated: Aug 4, 2026
DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by
1The Prostate Center at Vancouver General Hospital, University of British Columbia, Canada.
Abstract:
To develop a gene therapy that would selectively kill prostate cancer cells while sparing normal cells, we have constructed lentiviral vectors that contain a therapeutic gene with a short DNA sequence in the 5'-untranslated region (UTR) that is recognized by the translation initiation factor, eIF4E, which is often overexpressed in malignant cells. Infection of cancer (LNCaP, PC-3M, DU145, and MCF-7 cells) and noncancer cell lines (BPH-1, 267-B1, Plat-E, and Huvec-c cells) with lentivirus having a CMV-promoter and EGFP reporter resulted in high levels of EGFP expression in all cells, whereas, inclusion of the eIF4E UTR recognition sequence restricted high expression to cancer cells and Plat-E cells, which also express substantial levels of eIF4E. Infection of the cells with lentiviral vectors having this UTR in front of the HSV thymidine kinase suicide gene resulted in differential sensitivity to the killing effects of ganciclovir, with at least 100-fold more drug required to kill noncancer cells than cancer cells. Furthermore, in experiments where the CMV promoter was replaced by the prostate-specific ARR(2)PB promoter, the killing effects of ganciclovir were restricted to prostate cancer cells and not seen in nonprostate cancer cells. Our results indicate that combined translational regulation, by incorporation of an eIF4E-UTR recognition sequence into a therapeutic gene, together with transcriptional regulation with a prostate-specific promoter, may provide a means to selectively destroy prostate cancer cells while sparing normal prostate cells.
Insights
This gene therapy uses a special DNA sequence to target prostate cancer cells for destruction, sparing healthy cells. It combines translational and transcriptional regulation for selective cancer cell killing.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Prostate cancer cells often overexpress the translation initiation factor eIF4E.
- Developing targeted therapies to spare normal cells is crucial for effective cancer treatment.
Purpose of the Study:
- To engineer a gene therapy for selective prostate cancer cell killing.
- To utilize translational and transcriptional control for enhanced specificity.
Main Methods:
- Constructed lentiviral vectors with a therapeutic gene and an eIF4E-recognized 5'-UTR sequence.
- Infected cancer and non-cancer cell lines with vectors containing EGFP reporter or HSV thymidine kinase suicide gene.
- Utilized CMV and prostate-specific ARR(2)PB promoters for differential gene expression.
Main Results:
- The eIF4E UTR sequence restricted high expression to cancer cells.
- Lentiviral vectors with the suicide gene showed 100-fold greater sensitivity in cancer cells to ganciclovir.
- Prostate-specific promoter restricted ganciclovir's killing effect to prostate cancer cells.
Conclusions:
- Combined translational and transcriptional regulation offers a promising strategy for selective prostate cancer therapy.
- This approach can selectively destroy prostate cancer cells while sparing normal cells.
